Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inactivated Vaccine Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Children Inactivated Vaccine
1.2.3 Adult Inactivated Vaccine
1.3 Market by Application
1.3.1 Global Inactivated Vaccine Market Growth by Application: 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Medical Center
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Inactivated Vaccine Market Perspective (2018-2034)
2.2 Inactivated Vaccine Growth Trends by Region
2.2.1 Global Inactivated Vaccine Market Size by Region: 2018 VS 2022 VS 2034
2.2.2 Inactivated Vaccine Historic Market Size by Region (2018-2024)
2.2.3 Inactivated Vaccine Forecasted Market Size by Region (2024-2034)
2.3 Inactivated Vaccine Market Dynamics
2.3.1 Inactivated Vaccine Industry Trends
2.3.2 Inactivated Vaccine Market Drivers
2.3.3 Inactivated Vaccine Market Challenges
2.3.4 Inactivated Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inactivated Vaccine Players by Revenue
3.1.1 Global Top Inactivated Vaccine Players by Revenue (2018-2024)
3.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2018-2024)
3.2 Global Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Inactivated Vaccine Revenue
3.4 Global Inactivated Vaccine Market Concentration Ratio
3.4.1 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inactivated Vaccine Revenue in 2022
3.5 Inactivated Vaccine Key Players Head office and Area Served
3.6 Key Players Inactivated Vaccine Product Solution and Service
3.7 Date of Enter into Inactivated Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Inactivated Vaccine Breakdown Data by Type
4.1 Global Inactivated Vaccine Historic Market Size by Type (2018-2024)
4.2 Global Inactivated Vaccine Forecasted Market Size by Type (2024-2034)
5 Inactivated Vaccine Breakdown Data by Application
5.1 Global Inactivated Vaccine Historic Market Size by Application (2018-2024)
5.2 Global Inactivated Vaccine Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Inactivated Vaccine Market Size (2018-2034)
6.2 North America Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2034
6.3 North America Inactivated Vaccine Market Size by Country (2018-2024)
6.4 North America Inactivated Vaccine Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Inactivated Vaccine Market Size (2018-2034)
7.2 Europe Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2034
7.3 Europe Inactivated Vaccine Market Size by Country (2018-2024)
7.4 Europe Inactivated Vaccine Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Inactivated Vaccine Market Size (2018-2034)
8.2 Asia-Pacific Inactivated Vaccine Market Growth Rate by Region: 2018 VS 2022 VS 2034
8.3 Asia-Pacific Inactivated Vaccine Market Size by Region (2018-2024)
8.4 Asia-Pacific Inactivated Vaccine Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Inactivated Vaccine Market Size (2018-2034)
9.2 Latin America Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2034
9.3 Latin America Inactivated Vaccine Market Size by Country (2018-2024)
9.4 Latin America Inactivated Vaccine Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inactivated Vaccine Market Size (2018-2034)
10.2 Middle East & Africa Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2034
10.3 Middle East & Africa Inactivated Vaccine Market Size by Country (2018-2024)
10.4 Middle East & Africa Inactivated Vaccine Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharma(Japan)
11.1.1 Astellas Pharma(Japan) Company Detail
11.1.2 Astellas Pharma(Japan) Business Overview
11.1.3 Astellas Pharma(Japan) Inactivated Vaccine Introduction
11.1.4 Astellas Pharma(Japan) Revenue in Inactivated Vaccine Business (2018-2024)
11.1.5 Astellas Pharma(Japan) Recent Development
11.2 CSL Limited(Australia)
11.2.1 CSL Limited(Australia) Company Detail
11.2.2 CSL Limited(Australia) Business Overview
11.2.3 CSL Limited(Australia) Inactivated Vaccine Introduction
11.2.4 CSL Limited(Australia) Revenue in Inactivated Vaccine Business (2018-2024)
11.2.5 CSL Limited(Australia) Recent Development
11.3 Emergent BioSolutions(U.S.)
11.3.1 Emergent BioSolutions(U.S.) Company Detail
11.3.2 Emergent BioSolutions(U.S.) Business Overview
11.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Introduction
11.3.4 Emergent BioSolutions(U.S.) Revenue in Inactivated Vaccine Business (2018-2024)
11.3.5 Emergent BioSolutions(U.S.) Recent Development
11.4 GlaxoSmithKline(U.K.)
11.4.1 GlaxoSmithKline(U.K.) Company Detail
11.4.2 GlaxoSmithKline(U.K.) Business Overview
11.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Introduction
11.4.4 GlaxoSmithKline(U.K.) Revenue in Inactivated Vaccine Business (2018-2024)
11.4.5 GlaxoSmithKline(U.K.) Recent Development
11.5 Johnson & Johnson(U.S.)
11.5.1 Johnson & Johnson(U.S.) Company Detail
11.5.2 Johnson & Johnson(U.S.) Business Overview
11.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Introduction
11.5.4 Johnson & Johnson(U.S.) Revenue in Inactivated Vaccine Business (2018-2024)
11.5.5 Johnson & Johnson(U.S.) Recent Development
11.6 MedImmune(U.S.)
11.6.1 MedImmune(U.S.) Company Detail
11.6.2 MedImmune(U.S.) Business Overview
11.6.3 MedImmune(U.S.) Inactivated Vaccine Introduction
11.6.4 MedImmune(U.S.) Revenue in Inactivated Vaccine Business (2018-2024)
11.6.5 MedImmune(U.S.) Recent Development
11.7 Merck & Co(U.S.)
11.7.1 Merck & Co(U.S.) Company Detail
11.7.2 Merck & Co(U.S.) Business Overview
11.7.3 Merck & Co(U.S.) Inactivated Vaccine Introduction
11.7.4 Merck & Co(U.S.) Revenue in Inactivated Vaccine Business (2018-2024)
11.7.5 Merck & Co(U.S.) Recent Development
11.8 Pfizer(U.S.)
11.8.1 Pfizer(U.S.) Company Detail
11.8.2 Pfizer(U.S.) Business Overview
11.8.3 Pfizer(U.S.) Inactivated Vaccine Introduction
11.8.4 Pfizer(U.S.) Revenue in Inactivated Vaccine Business (2018-2024)
11.8.5 Pfizer(U.S.) Recent Development
11.9 Sanofi Pasteur(France)
11.9.1 Sanofi Pasteur(France) Company Detail
11.9.2 Sanofi Pasteur(France) Business Overview
11.9.3 Sanofi Pasteur(France) Inactivated Vaccine Introduction
11.9.4 Sanofi Pasteur(France) Revenue in Inactivated Vaccine Business (2018-2024)
11.9.5 Sanofi Pasteur(France) Recent Development
11.10 Serum Institute of India Pvt(India)
11.10.1 Serum Institute of India Pvt(India) Company Detail
11.10.2 Serum Institute of India Pvt(India) Business Overview
11.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Introduction
11.10.4 Serum Institute of India Pvt(India) Revenue in Inactivated Vaccine Business (2018-2024)
11.10.5 Serum Institute of India Pvt(India) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Inactivated Vaccine Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2034
Table 2. Key Players of Children Inactivated Vaccine
Table 3. Key Players of Adult Inactivated Vaccine
Table 4. Global Inactivated Vaccine Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2034
Table 5. Global Inactivated Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Table 6. Global Inactivated Vaccine Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Inactivated Vaccine Market Share by Region (2018-2024)
Table 8. Global Inactivated Vaccine Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 9. Global Inactivated Vaccine Market Share by Region (2024-2034)
Table 10. Inactivated Vaccine Market Trends
Table 11. Inactivated Vaccine Market Drivers
Table 12. Inactivated Vaccine Market Challenges
Table 13. Inactivated Vaccine Market Restraints
Table 14. Global Inactivated Vaccine Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Inactivated Vaccine Market Share by Players (2018-2024)
Table 16. Global Top Inactivated Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2022)
Table 17. Ranking of Global Top Inactivated Vaccine Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Inactivated Vaccine Revenue (CR5 and HHI) & (2018-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Inactivated Vaccine Product Solution and Service
Table 21. Date of Enter into Inactivated Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Inactivated Vaccine Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Inactivated Vaccine Revenue Market Share by Type (2018-2024)
Table 25. Global Inactivated Vaccine Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 26. Global Inactivated Vaccine Revenue Market Share by Type (2024-2034)
Table 27. Global Inactivated Vaccine Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Inactivated Vaccine Revenue Market Share by Application (2018-2024)
Table 29. Global Inactivated Vaccine Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 30. Global Inactivated Vaccine Revenue Market Share by Application (2024-2034)
Table 31. North America Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2034
Table 32. North America Inactivated Vaccine Market Size by Country (2018-2024) & (US$ Million)
Table 33. North America Inactivated Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 34. Europe Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2034
Table 35. Europe Inactivated Vaccine Market Size by Country (2018-2024) & (US$ Million)
Table 36. Europe Inactivated Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 37. Asia-Pacific Inactivated Vaccine Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2034
Table 38. Asia-Pacific Inactivated Vaccine Market Size by Region (2018-2024) & (US$ Million)
Table 39. Asia-Pacific Inactivated Vaccine Market Size by Region (2024-2034) & (US$ Million)
Table 40. Latin America Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2034
Table 41. Latin America Inactivated Vaccine Market Size by Country (2018-2024) & (US$ Million)
Table 42. Latin America Inactivated Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 43. Middle East & Africa Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2034
Table 44. Middle East & Africa Inactivated Vaccine Market Size by Country (2018-2024) & (US$ Million)
Table 45. Middle East & Africa Inactivated Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 46. Astellas Pharma(Japan) Company Detail
Table 47. Astellas Pharma(Japan) Business Overview
Table 48. Astellas Pharma(Japan) Inactivated Vaccine Product
Table 49. Astellas Pharma(Japan) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 50. Astellas Pharma(Japan) Recent Development
Table 51. CSL Limited(Australia) Company Detail
Table 52. CSL Limited(Australia) Business Overview
Table 53. CSL Limited(Australia) Inactivated Vaccine Product
Table 54. CSL Limited(Australia) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 55. CSL Limited(Australia) Recent Development
Table 56. Emergent BioSolutions(U.S.) Company Detail
Table 57. Emergent BioSolutions(U.S.) Business Overview
Table 58. Emergent BioSolutions(U.S.) Inactivated Vaccine Product
Table 59. Emergent BioSolutions(U.S.) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 60. Emergent BioSolutions(U.S.) Recent Development
Table 61. GlaxoSmithKline(U.K.) Company Detail
Table 62. GlaxoSmithKline(U.K.) Business Overview
Table 63. GlaxoSmithKline(U.K.) Inactivated Vaccine Product
Table 64. GlaxoSmithKline(U.K.) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 65. GlaxoSmithKline(U.K.) Recent Development
Table 66. Johnson & Johnson(U.S.) Company Detail
Table 67. Johnson & Johnson(U.S.) Business Overview
Table 68. Johnson & Johnson(U.S.) Inactivated Vaccine Product
Table 69. Johnson & Johnson(U.S.) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 70. Johnson & Johnson(U.S.) Recent Development
Table 71. MedImmune(U.S.) Company Detail
Table 72. MedImmune(U.S.) Business Overview
Table 73. MedImmune(U.S.) Inactivated Vaccine Product
Table 74. MedImmune(U.S.) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 75. MedImmune(U.S.) Recent Development
Table 76. Merck & Co(U.S.) Company Detail
Table 77. Merck & Co(U.S.) Business Overview
Table 78. Merck & Co(U.S.) Inactivated Vaccine Product
Table 79. Merck & Co(U.S.) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 80. Merck & Co(U.S.) Recent Development
Table 81. Pfizer(U.S.) Company Detail
Table 82. Pfizer(U.S.) Business Overview
Table 83. Pfizer(U.S.) Inactivated Vaccine Product
Table 84. Pfizer(U.S.) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 85. Pfizer(U.S.) Recent Development
Table 86. Sanofi Pasteur(France) Company Detail
Table 87. Sanofi Pasteur(France) Business Overview
Table 88. Sanofi Pasteur(France) Inactivated Vaccine Product
Table 89. Sanofi Pasteur(France) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 90. Sanofi Pasteur(France) Recent Development
Table 91. Serum Institute of India Pvt(India) Company Detail
Table 92. Serum Institute of India Pvt(India) Business Overview
Table 93. Serum Institute of India Pvt(India) Inactivated Vaccine Product
Table 94. Serum Institute of India Pvt(India) Revenue in Inactivated Vaccine Business (2018-2024) & (US$ Million)
Table 95. Serum Institute of India Pvt(India) Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Inactivated Vaccine Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Inactivated Vaccine Market Share by Type: 2022 VS 2034
Figure 3. Children Inactivated Vaccine Features
Figure 4. Adult Inactivated Vaccine Features
Figure 5. Global Inactivated Vaccine Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 6. Global Inactivated Vaccine Market Share by Application: 2022 VS 2034
Figure 7. Hospital Case Studies
Figure 8. Medical Center Case Studies
Figure 9. Inactivated Vaccine Report Years Considered
Figure 10. Global Inactivated Vaccine Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 11. Global Inactivated Vaccine Market Size, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Inactivated Vaccine Market Share by Region: 2022 VS 2034
Figure 13. Global Inactivated Vaccine Market Share by Players in 2022
Figure 14. Global Top Inactivated Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2022)
Figure 15. The Top 10 and 5 Players Market Share by Inactivated Vaccine Revenue in 2022
Figure 16. North America Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 17. North America Inactivated Vaccine Market Share by Country (2018-2034)
Figure 18. United States Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 19. Canada Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 20. Europe Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 21. Europe Inactivated Vaccine Market Share by Country (2018-2034)
Figure 22. Germany Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 23. France Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. U.K. Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 25. Italy Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 26. Russia Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. Nordic Countries Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 28. Asia-Pacific Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 29. Asia-Pacific Inactivated Vaccine Market Share by Region (2018-2034)
Figure 30. China Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. Japan Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. South Korea Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. Southeast Asia Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. India Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. Australia Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Latin America Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. Latin America Inactivated Vaccine Market Share by Country (2018-2034)
Figure 38. Mexico Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 39. Brazil Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 40. Middle East & Africa Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 41. Middle East & Africa Inactivated Vaccine Market Share by Country (2018-2034)
Figure 42. Turkey Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. Saudi Arabia Inactivated Vaccine Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. Astellas Pharma(Japan) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 45. CSL Limited(Australia) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 46. Emergent BioSolutions(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 47. GlaxoSmithKline(U.K.) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 48. Johnson & Johnson(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 49. MedImmune(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 50. Merck & Co(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 51. Pfizer(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 52. Sanofi Pasteur(France) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 53. Serum Institute of India Pvt(India) Revenue Growth Rate in Inactivated Vaccine Business (2018-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed